// App-Quantinova.ai

BSH2020‐PO‐015 : Synergistic inhibition of FLT3‐ITD acute myeloid leukaemia cell growth in vitro using combination of FLT3 inhibitor quizartinib and standard of care chemotherapeutic agent cytarabine

Researchers

Presenter

  • S. Darici

Principal Investigators

  • M. Zavatti

  • H. Alkhaldi

  • L. Braglia

  • H. G. Jrgensen

  • G. Horne

  • S. Marmiroli

  • X. Huang

Medical Centers

  • Paul O?Gorman Leukaemia Research Centre, University of Glasgow, Glasgow, United Kingdom

  • Department of Biomedical, Metabolic and Neural Sciences

  • Department of Surgical, Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, Modena, Italy

Locations

  • United Kingdom

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute myelocytic leukemia

Biomarkers

  • Mitogen-activated protein kinase

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

  • Extracellular signal-regulated kinase

  • Fms related tyrosine kinase 3

  • Janus kinase

  • Serine/threonine-protein kinase mTOR

  • Signal transducer and activator of transcription 5

  • PI3K/AKT

  • MAPK/ERK

Drug/Treatment

  • quizartinib

  • Cytarabine liposomal

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved